Evidence map›Paper›PMID 34560279›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022

Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis.

Sean M Morris, Matthew J Armstrong, Philip N Newsome

Open access · bronzeAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Role of Exercise in Steatotic Liver Diseases: An Updated Perspective.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sean M MorrisCentre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Matthew J ArmstrongNational Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Philip N NewsomeNational Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
University of Birmingham · GBNational Institute for Health Research · GB

Funding

Department of Health
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide 1HumansLiver CirrhosisGlucagon-Like Peptide 1Hypoglycemic Agents

Identifiers

PMID34560279
OpenAlexW3201023005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.